Dimephosphon Effects on Skin Microhaemodynamics

Чуян, Е. Н.; Раваева, М. Ю.; Нефедов, Д. А.; Зеленская, А. В.; Галенко-ярошевский, П. А.

doi:10.25207/1608-6228-2017-24-5-90-95

Cited by 3 publications

(3 citation statements)

References 4 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study of the effect of a new injectable form of Rexod® on microhemocirculation (MHС) in the rat skin was performed by laser Doppler fluometry method, described by Chuyan et al (2017) and Galenko-Yaroshevsky et al (2018). Following non-oscillatory data of basal blood flow were recorded: microcirculation indicators, standard deviations, and coefficients of variation.…”

Section: Methodsmentioning

confidence: 99%

Mafusol and its combination with REXOD as correctors of reduced blood circulation in the skin associated with normoglycemia or diabetes mellitus complicated by exogenous hypercholesterolemia

Gulevskaya¹,

Galenko-Yaroshevsky²,

Лебедева³

et al. 2021

RRP

View full text Add to dashboard Cite

Introduction: The search for and development of new highly active medications and their combinations of the appropriate direction of action remains an urgent problem due to the complications of diabetes mellitus, especially burdened with atherosclerosis, including skin and vascular lesions. Materials and methods: The acute toxicity, histoprotective and dermatoprotective effects of mafusol, rexod, alprostadil and their combinations were studied in male rats with normoglycemia and alloxan diabetes complicated by exogenous hypercholesterolemia. Results: The combination of mafusol with rexod is less toxic than mafusol. In arteriovenous insufficiency of the tail, ischemia of the skin fold and skin flap, mafusol (6.25, 12.5 and 25.0 mg/kg in terms of fumarate), rexod (0.01 and 0.02 mg/kg) and especially their combination (6.25 and 0.01 mg/kg) have significant histoprotective, dermatoprotective, hypoglycemic and lipid-lowering effects, both in normoglycemia and alloxan diabetes complicated by exogenous hypercholesterolemia. Alprostadil (10 mg/kg) and especially its combination with mafusol (6.25 mg/kg) have a dermatoprotective effect. Discussion: Rexod reduces the acute toxicity of mafusol. The dermatoprotective effect of mafusol, rexod and, to a greater extent, their combination may be associated with increased microhemocirculation, antihypoxic properties and activation of energy processes in the skin, normalization of carbohydrate and lipid metabolism in alloxan diabetes, complicated by exogenous hypercholesterolemia, increased reserve capacity of the antioxidant system, and possibly with the ability of mafusol and rexod to reduce blood viscosity and improve rheological properties of the blood. The combination of mafusol with alprostadil increases the dermatoprotective activity of the latter. Conclusion: Combinations of mafusol with rexod and alprostadil can be recommended for clinical study as dermatoprotective agents for treating traumatic injuries and diabetes mellitus complicated by atherosclerosis.

show abstract

Section: Methodsmentioning

confidence: 99%

Mafusol and its combination with REXOD as correctors of reduced blood circulation in the skin associated with normoglycemia or diabetes mellitus complicated by exogenous hypercholesterolemia

Gulevskaya¹,

Galenko-Yaroshevsky²,

Лебедева³

et al. 2021

RRP

View full text Add to dashboard Cite

show abstract

“…Используя вейвлет-анализ определяли амплитуды пульсации потока крови (АППК) в микрососудах кожи в диапазонах следующих частот: 0,0095-0,02, 0,02-0,046, 0,07-0,15, 0,15-0,4 и 0,8-0,16 Гц, отражающих соответственно эндотелиальные (АэП), нейрогенные (АнП), миогенные (АмП), дыхательные (АдП) и пульсовые (АпП) процессы. Учитывая тот факт, что при проведении экспериментов имела место вариабельность колебаний АППК, их нормированный параметр вычисляли по формуле [18]: Выявленные изменения показателей МГЦ в коже крыс, спустя 15 мин после инъецирования НИФ Рексода ® , нашли своё отражение и в повышении интегральных показателей базального микрокровотока. Так, показатель ПМ увеличивался на 33,4%, СКО -на 14,0% и Квна 27,6% по отношению к аналогичным показателям в контрольной группе животных.…”

Section: средиunclassified

“…Всевозрастающий интерес специалистов различных отраслей медицины к СОД объясняется её диагностической [4][5][6] и прогностической [7] значимостью, высокой лечебной активностью при многих патологических процессах [8][9][10][11][12][13]. [18,19,20].…”

Section: Introductionunclassified

Impact of new Rexod® injection form on blood microcirculation in rat skin

Tseluiko

Задорожний

Чуян

et al. 2020

Kuban. nauсh. med. vestnik

Self Cite

View full text Add to dashboard Cite

Background. Free radical oxidation underlies many morbid processes in various organs and tissues, including skin. A major antioxidant preventing the free radical impact is superoxide dismutase (SOD). A particularly valued SOD-containing agent is recombinant human SOD, Rexod, possessing a wide spectrum of medical applications in form of lyophilisate. Marketing of a new Rexod® injection preparation in form of solution requires research into its properties, including the impact on blood microcirculation in skin, especially with the lack of relevant clinical trials.Objectives. Evaluation of anticipated positive effects of the new injection form of Rexod® on blood microcirculation in rat skin.Мethods. The new Rexod® preparation impact on blood microcirculation in skin was studied with laser Doppler fl uometry by recording the following non-oscillatory parameters of the basal blood fl ow: microcirculation (MC), mean squared deviation (MSD) and coeffi cient of variation (CV). Blood fl ow fl uctuations were measured in a wavelet analysis at different frequency bands: 0.0095–0.02, 0.02–0.046, 0.07–0.15, 0.15–0.4 and 0.8–0.16 Hz corresponding to endothelial (Ae), neurogenic (An), myogenic (Am), respiratory (Ar) and pulse (Ap) rhythm amplitudes, respectively.Results. The new Rexod® injection preparation at a dose of 8000 U/kg after 15 min of intraperitoneal administration in rats caused a statistically signifi cant (p < 0.05) increase in the blood fl ow fl uctuation amplitudes Ae (43.1%), An (43.4%), Am (60.8%), Ar (58.3%) and Ap (32.0%) compared to the control group. Because the Ae fl uctuations coincide with nitric oxide (NO) emission episodes, such a growth indicates an elevated NO excretion by endothelial cells leading to endothelium-dependent vasodilation. The observed changes in blood microcirculation in skin are also associated with higher integral values of the basal blood fl ow, MC (33.4% increase), MSD (14.0%) and CV (27.6%), although only MC and CV values were statistically signifi cant (p < 0.05). The results obtained suggest that the new injection form of Rexod® stimulates endothelial NO excretion, exerts adrenergic relaxation in smooth muscle cells of arteriolae and arteriovenular anastomoses, reduces precapillary sphincter and arteriolar contractility through Ca2+-dependent muscle relaxation, affects respiratory modulation of the venular blood microcirculatory compartment and vegetative cardiac support, intensifi es arterial blood fl ow by increasing the cardiac output.Conclusion. Application of the new Rexod® injection form improves blood microdynamics in rat skin via stimulating endothelium-dependent and independent vasodilatation and endothelial metabolism, decelerating adrenergic vasomotor activity and peripheral microvascular resistance. These processes in coupling improve blood fl ow to nutritive microvascular bed and normalise venular outfl ow. Our results provide further insights into pharmacodynamics of recombinant human SOD (Rexod).

show abstract

Antioxidant therapy in the complex treatment of patients with ischemic stroke in the acute and recovery period

Belova

Котов

2023

RJTAO

View full text Add to dashboard Cite

Improvement of therapy of patients with ischemic stroke (IS) remains a relevant problem, despite the widespread use of drug and mechanical revascularization methods during recent years. One of the pathogenetic mechanisms of IS is oxidative stress as one of the components of brain tissue damage in the acute period and a factor that prevents the processes of repair and neuroplasticity in the recovery period. This is the rationale for the use of antioxidant drugs in the acute and recovery periods of stroke. Data from clinical studies on the use of antioxidants in the treatment of patients with IS are presented. We describe the use of the domestic drug dimephosphone (dimethyloxobutylphosphonyl dimethylate), a synthetic non-anticholinesterase organophosphorus compound, which has a wide range of effects: antioxidant, antacidotic, vasodilating, membrane stabilizing, anti-inflammatory, etc. Data are given on the use of dimephosphone in the acute period of IS in patients with no indications for thrombolytic therapy, there was a decrease in neurological deficit and a decrease in disability. The positive results of the use of dimephosphone in the recovery period of IS and in chronic cerebrovascular insufficiency are described. The data of our own study on the use of dimephosphone in the complex therapy of cognitive rehabilitation of patients in the recovery period of IS are presented. A statistically significant recovery of cognitive functions was registered according to the Montreal Cognitive Scale (MoCA), and an increase in the MoCA score by 2 points or more in 59.6% of patients. An improvement in executive functions, an increase in the flexibility of cognitive control of cognitive processes, and the predominance of verbal thinking over sensory-perceptual were noted.

show abstract

Dimephosphon Effects on Skin Microhaemodynamics

Cited by 3 publications

References 4 publications

Mafusol and its combination with REXOD as correctors of reduced blood circulation in the skin associated with normoglycemia or diabetes mellitus complicated by exogenous hypercholesterolemia

Mafusol and its combination with REXOD as correctors of reduced blood circulation in the skin associated with normoglycemia or diabetes mellitus complicated by exogenous hypercholesterolemia

Impact of new Rexod® injection form on blood microcirculation in rat skin

Antioxidant therapy in the complex treatment of patients with ischemic stroke in the acute and recovery period

Contact Info

Product

Resources

About